Paediatric Benznidazole

Result of a three-year collaborative partnership, starting in 2008, between DNDi and the Pernambuco State Pharmaceutical Laboratory (Laboratório Farmacêutico do Estado de Pernambuco; LAFEPE) of Brazil. LAFEPE is the second largest public laboratory in Brazil and the only producer of benznidazole in the world.


An improved treatment option

  • First paediatric drug
  • Age-adapted, easy-to-use, affordable, and non-patented tablet, for the treatment of Chagas
  • Disease in infants and young children under two years of age (20 kg body weight)
  • Contributes to improved dosing accuracy, safety, and adherence to treatment
  • Registered in Brazil
  • On WHO Essential Medicines List (children)
  • Collaboration with Mundo Sano Foundation to deliver a second source of treatment with Laboratorio ELEA, Argentina
  • Granted registration by Brazil’s National Health Surveillance Agency (ANVISA), with further endemic countries targeted for obtaining registration

Main advantages of the Paediatric dosage form of Benznidazole

  • A single tablet allows coverage of a wide age range, up to two years old or body weight 20 kg
  • Child-adapted dose of 12.5 mg per tablet taken twice daily for 60 days
  • Easily dispersible tablet to facilitate oral administration
  • No need for tablet fractionation (except for low-birth weight babies <2.5 kg: half a tablet)
  • Simple and reliable administration that does not require complex preparation and can therefore be administered at home, even during the long duration of treatment (twice daily for 60 days)





Paediatric Benznidazole News

Watch PaedBenz Videos

Portuguese 6’30”
Spanish      6’30”
English       6’30”

Granted registration in Brazil in late 2011!

Isabela Ribeiro, Poster
Population Pharmacokinetics of Benznidazole in Children…